997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
United States
609 896 9100
https://www.imunon.com
Settore/i:
Settore:
Impiegati a tempo pieno: 31
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Michael H. Tardugno | Executive Chairman | 1,58M | N/D | 1951 |
Mr. Jeffrey W. Church CPA | CFO, Executive VP & Corporate Secretary | 548,92k | N/D | 1957 |
Dr. Khursheed Anwer M.B.A., Ph.D. | Executive VP & Chief Scientific Officer | 540,87k | N/D | 1960 |
Mr. Timothy J. Tumminello CPA | Chief Accounting Officer & Controller | 108,31k | N/D | 1958 |
Ms. Marianne M. Lambertson | Vice President of Communications & Investor Relations | N/D | N/D | N/D |
Dr. Sebastien Hazard M.D. | Executive VP & Chief Medical Officer | N/D | N/D | 1972 |
Imunon, Inc., a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma. It also has two platform technologies, such as TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies; and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
L'ISS Governance QualityScore di Imunon, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.